Comparative Pharmacology
Head-to-head clinical analysis: WOLFINA versus ZOVIA 1 35E 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: WOLFINA versus ZOVIA 1 35E 28.
WOLFINA vs ZOVIA 1/35E-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not specified in available data; likely unapproved or investigational drug.
ZOVIA 1/35E-28 is a combined oral contraceptive (COC) containing ethinyl estradiol and norethindrone. It inhibits ovulation via suppression of gonadotropins (FSH and LH), increases cervical mucus viscosity, and alters endometrial receptivity.
Initial: 50 mg orally twice daily. Titrate to 100 mg twice daily after 2 weeks based on tolerability.
One tablet orally once daily at the same time each day for 21 days, followed by 7 days of placebo (inactive tablets), then repeat.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Ethinyl estradiol: ~17 hours (range 13-27 hours); Norethindrone: ~8 hours (range 5-14 hours). Clinical context: Steady state achieved in ~5-7 days; contraceptive effect requires consistent dosing.
Primarily renal (70% unchanged), with 20% biliary/fecal and 10% metabolic degradation.
Renal: ~40% as metabolites; biliary/fecal: ~40% as metabolites; unchanged drug minimal (<1%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive